PASADENA, Calif., March 6,
2025 /PRNewswire/ -- Alexandria Real Estate Equities,
Inc. (NYSE: ARE), the first, preeminent, longest-tenured and
pioneering owner, operator and developer of collaborative
Megacampus™ ecosystems in AAA life science innovation
cluster locations, today announced that the company's board of
directors has elected Claire
Aldridge, PhD, as an independent director, effective
March 14, 2025. The board of
directors has also appointed Dr. Aldridge to serve as a member of
its Life Science Committee and determined that she is independent
in accordance with New York Stock Exchange listing standards and
Securities and Exchange Commission rules. Her term will run until
the company's 2025 annual meeting of stockholders.
"Dr. Aldridge's distinguished career in the life science
industry spans more than 25 years across biotechnology, venture
capital, entrepreneurship, technology commercialization and
AI-accelerated therapeutic development," said Joel S. Marcus, executive chairman and founder
of Alexandria Real Estate Equities, Inc. and Alexandria Venture
Investments. "Her deep business and scientific experience, which
includes facilitating the translation of scientific discoveries
into innovative therapies that improve patient lives, will further
bolster the combined expertise of our board, and we are honored to
welcome her."
Dr. Aldridge was the chief strategy officer of Form Bio, the
first spinout from the de-extinction and biodiversity company
Colossal Biosciences. At Form Bio, Dr. Aldridge led the integration
of artificial intelligence and machine learning into genomic
analysis and advanced therapeutics programs, such as gene therapy,
biological sequence alignment and directed evolution, to accelerate
the development of safe and effective new medicines. She also
oversaw the generation of vast proprietary datasets needed to train
sophisticated AI models. Prior to Form Bio, Dr. Aldridge served as
senior vice president, chief of staff and business operations at
Taysha Gene Therapies, a clinical-stage biotechnology company
focused on advancing gene therapies for severe monogenic diseases
of the central nervous system. She was previously associate vice
president of commercialization and business development at UT
Southwestern Medical Center and vice president of venture
development at Remeditex Ventures.
Dr. Aldridge currently serves on the scientific advisory board
of Colossal Biosciences and on the board of directors of 4E
Therapeutics. She is also a member of the Product Development
Advisory Committee of the Cancer Prevention and Research Institute
of Texas (CPRIT), the $6 billion state agency established to help
Texans conquer cancer; a founding advisor for Nucleate Texas, a
non-profit organization dedicated to empowering the next generation
of biotechnology leaders; a participant in Duke University's Entrepreneurial Leaders Network;
and past chair of the Industrial Advisory Board of Bioengineering
at UT Dallas. In April 2023, she was named one of Forbes' 10 women
leading the synthetic biology revolution.
Dr. Aldridge received her PhD from Duke
University in the Department of Immunology and the Program
in Genetics and Genomics and her Bachelor of Science degree in
Biomedical Science from Texas A&M
University.
About Alexandria Real Estate Equities, Inc.
Alexandria
Real Estate Equities, Inc. (NYSE: ARE), an S&P
500® company, is a best-in-class, mission-driven
life science REIT making a positive and lasting impact on the
world. With our founding in 1994, Alexandria pioneered the life science real
estate niche. Alexandria is the
preeminent and longest-tenured owner, operator and developer of
collaborative Megacampus™ ecosystems in AAA life science
innovation cluster locations, including Greater Boston, the San Francisco Bay Area, San Diego, Seattle, Maryland, Research Triangle and New York City. As of December 31, 2024, Alexandria has a total market capitalization
of $29.0 billion and an asset base in
North America that includes 39.8
million RSF of operating properties and 4.4 million RSF of Class
A/A+ properties undergoing construction. Alexandria has a longstanding and proven track
record of developing Class A/A+ properties clustered in highly
dynamic and collaborative Megacampus environments that enhance our
tenants' ability to successfully recruit and retain world-class
talent and inspire productivity, efficiency, creativity and
success. Alexandria also provides
strategic capital to transformative life science companies through
our venture capital platform. We believe our unique business model
and diligent underwriting ensure a high-quality and diverse tenant
base that results in higher occupancy levels, longer lease terms,
higher rental income, higher returns and greater long-term asset
value. For more information on Alexandria, please visit www.are.com.
Forward-Looking Statements
This press release includes "forward-looking statements" within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended.
Such forward-looking statements include, without limitation,
statements regarding the potential impacts of a director's
appointment to the company's board of directors and expectations
regarding the company's performance and success. These
forward-looking statements are based on Alexandria's present intent, beliefs or
expectations, but forward-looking statements are not guaranteed to
occur and may not occur. Actual results may differ materially from
those contained in or implied by Alexandria's forward-looking statements as a
result of a variety of factors, including, without limitation, the
risks and uncertainties detailed in its filings with the Securities
and Exchange Commission. All forward-looking statements are made as
of the date of this press release, and Alexandria assumes no obligation to update
this information. For more discussion relating to risks and
uncertainties that could cause actual results to differ materially
from those anticipated in Alexandria's forward-looking statements, and
risks and uncertainties to Alexandria's business in general, please refer
to Alexandria's filings with the
Securities and Exchange Commission, including its most recent
annual report on Form 10-K and any subsequently filed quarterly
reports on Form 10-Q.
CONTACT: Sara
Kabakoff, Senior Vice President – Chief Content Officer,
(626) 788-5578, skabakoff@are.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/alexandria-real-estate-equities-inc-elects-claire-aldridge-phd-to-board-of-directors-302393735.html
SOURCE Alexandria Real Estate Equities, Inc.
